A new meningococcal B vaccine for adolescents and adults: characteristics and methods of use

Area of Science:

• Immunology
• Vaccinology
• Infectious Diseases

Background:

• Neisseria meningitidis causes life-threatening meningitis and sepsis across all age groups.
• Paediatric and adolescent populations exhibit the highest incidence of meningococcal disease.
• Effective prevention strategies include conjugated polysaccharide vaccines (MenACWY) and meningococcal B (MenB) protein vaccines.

Purpose of the Study:

• To evaluate the efficacy and optimal dosing schedule of the Trumenba® vaccine against meningococcal serogroup B invasive disease.
• To determine if a 2-dose schedule of Trumenba® can elicit a protective immune response comparable to a 3-dose schedule in adolescents and young adults.

Main Methods:

• The study focuses on the bivalent, recombinant Trumenba® vaccine, approved by the European Medicine Agency (EMA) for individuals aged 10 years and older.
• Comparative analysis of immune responses induced by a 2-dose (0-6 months) versus a 3-dose schedule of Trumenba® in adolescents and young adults.

Main Results:

• A 2-dose (0-6 months) schedule of Trumenba® induces a protective immune response in adolescents and young adults.
• This response is comparable to that achieved with a 3-dose schedule.
• The 2-dose schedule is recommended for routine use.

Conclusions:

• The Trumenba® vaccine should be routinely administered using a 2-dose schedule (0-6 months) for meningococcal B disease prevention in eligible populations.
• A 3-dose schedule may be considered for specific high-risk individuals (e.g., asplenia, complement deficiency) or during epidemics.
• Routine 3-dose vaccination is not necessary for individuals with underlying conditions like diabetes or heart disease.